Completed master course of Graduate School of Medicine, the University of Tokyo.
After engaging in cancer basic research in academia, he was in charge of MOA analysis of small molecule drugs, biomarker development, global clinical trials, and out-licensing activities as a project manager at FUJIFLM. Moved to BMS and led observational research and domestic and international clinical trials of various assets such as immune checkpoint inhibitors and CAR-T treatments. Utilizing his career experience in the entire process of drug discovery, from lead compound development to new drug approval, including FDA/PMDA correspondence, he provides investment decision support and hands-on support to drug discovery ventures. A member of the Japanese Cancer Association.
In 2024, he joined KII as a venture partner.